INVO Fertility (IVF): Can It Reach $1.00 After a +56% Recovery?
Key Takeaways
- The central target used here is $1.00, a market-structure milestone tied to Nasdaq's $1.00 minimum bid price rule and a psychological round number, rather than an analyst-derived price target.
- From a recent close near $0.64, reaching $1.00 would require a gain of roughly 56%, a substantial move for a heavily diluted micro-cap.
- Analyst coverage is extremely thin: the only clearly attributable recent target is Maxim Group's $4.00 (Buy, February 10, 2026), which predates the March 2026 reverse split and the stock's collapse.
- Some data aggregators display a $20.00 figure that appears tied to reverse-split adjustments rather than multiple independent current forecasts.
- The strongest supporting factor would be a return to Nasdaq compliance and any improvement in the company's still-negative earnings trajectory.
- The biggest risks are continued operating losses, a delayed annual 10-K filing, recurring reverse splits, and persistent selling pressure on the shares.
- For more on the ticker's Major News, Today's Price Move, Forecast, and Earnings, visit the dedicated IVF pages.
- Explore Trending AI Robots to see AI-driven trading strategies applied across the market.
Analyst Coverage and Price Targets
IVF lacks a meaningful current analyst consensus. The most recent clearly attributable rating is a Buy from Maxim Group with a $4.00 price target issued on February 10, 2026. That call came before the company's 1-for-5 reverse split in March 2026 and the stock's subsequent decline, so it provides limited guidance for today's sub-dollar price. Aggregators show divergent figures — MarketWatch lists a single $4.00 target, while others display $20.00 — a spread that most plausibly reflects mechanical reverse-split adjustments rather than several independent, current forecasts. Because fewer than two credible, current targets exist, no reliable average analyst price target can be calculated, and the $1.00 level is used instead as a market-structure objective drawn from Nasdaq's listing rules and public discussion of the company's compliance challenges. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Current Market Position and Path to the Target
The shares have fluctuated roughly between $0.64 and $1.00 in recent weeks, with a mid-October 2026 close near $0.64, reflecting extraordinary volatility. Reaching $1.00 from that level implies a roughly 56% gain — a substantial move. A path toward it would most likely run through a stabilization of the share price, renewed institutional or retail interest, and concrete progress on the company's finances and regulatory filings. INVO Fertility generates modest revenue (about $7.5 million trailing) but remains unprofitable, and it has delayed its annual 10-K filing citing tax-related review delays, which has weighed on confidence.
Factors That Could Support a Move Higher
A rebound toward $1.00 could be supported by restored Nasdaq compliance, an improvement in the company's cash position, or evidence that its fertility clinic model is moving toward profitability. The company's strategic focus narrowed in 2025 to fertility care after divesting its oncology operations, which simplified the business. Its INVOcell device offers a lower-cost alternative to traditional in vitro fertilization, a positioning that could appeal to value-conscious patients. Any positive developments in filings, financing, or clinic-level margins could help sentiment recover.
Key Risks That Could Keep the Target Out of Reach
The obstacles are substantial. The company is unprofitable and has relied on repeated reverse stock splits to maintain its Nasdaq listing, a pattern that has eroded shareholder value. The delayed 10-K filing introduces accounting and governance uncertainty. Micro-cap fertility names face intense competition from larger, better-capitalized clinic operators, and a sub-$1 share price heightens delisting risk. Sustained selling pressure, dilution, and weak fundamentals could keep the stock below $1.00 or drive it lower.
Technical Levels and Market Structure
$1.00 is both a psychological round number and the Nasdaq minimum bid threshold, making it the most durable nearby level to watch. Trading below it places the shares in penny-stock territory with associated compliance risk. Above that, the stock's post-split reference points — including the roughly $2.68 level recorded around the March 2026 reverse split — represent further resistance. The long-term structure remains a downtrend, marked by deep drawdowns and reduced trading liquidity. From what I see, this level deserves close attention given the compliance backdrop.
Time Horizon and What to Monitor
Because the $1.00 target is a compliance and technical milestone rather than an analyst target, no specific 12-month horizon applies. Investors should monitor the company's next earnings releases, the resolution of the delayed annual report, any financing or dilution announcements, and Nasdaq compliance communications. Nasdaq delisting notices, further reverse splits, or new capital raises would be decisive for the stock's near-term direction. I’m watching this closely as developments unfold.
Final Assessment
Can INVO Fertility (IVF) reach $1.00? The target is achievable in principle but requires a substantial — roughly 56% — recovery from recent levels, against a backdrop of continued losses, a delayed filing, and a history of reverse splits. There is no reliable analyst consensus to lean on; the single dated Maxim Group target of $4.00 offers little help for today's price. The clearest catalysts are Nasdaq compliance, financing, and any sign of progress toward profitability, while dilution and delisting risk remain the principal threats. Investors should watch the next filings and earnings updates closely rather than relying on any single forecast.
AI Daily Buy/Sell Signals
Tickeron's AI Daily Buy/Sell Signals use artificial intelligence to continuously monitor thousands of stocks and ETFs and generate Buy, Sell, or Hold signals as market conditions evolve. The system analyzes technical behavior and AI-driven data to help traders discover opportunities, track positions, and spot changing trends more efficiently than manual screening. For a volatile micro-cap such as IVF, where moves can be sharp and sentiment-driven, a systematic signal layer can help separate short-term noise from genuine directional shifts. Traders can explore the AI Daily Buy/Sell Signals page to see how these automated insights apply to their own watchlists. In my view, this tool has become a useful part of my regular research process for names like this.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
Momentum Indicator for IVF turns negative, indicating new downward trend
IVF saw its Momentum Indicator move below the 0 level on September 24, 2026. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 81 similar instances where the indicator turned negative. In 78 of the 81 cases, the stock moved further down in the following days. The odds of a decline are at 90%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Moving Average Convergence Divergence Histogram (MACD) for IVF turned negative on October 01, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 42 similar instances when the indicator turned negative. In 41 of the 42 cases the stock turned lower in the days that followed. This puts the odds of success at 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where IVF declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for IVF entered a downward trend on October 23, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The RSI Indicator shows that the ticker has stayed in the oversold zone for 15 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an Uptrend is expected.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 19 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +4.34% 3-day Advance, the price is estimated to grow further. Considering data from situations where IVF advanced for three days, in 157 of 191 cases, the price rose further within the following month. The odds of a continued upward trend are 82%.
IVF may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 48 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.089) is normal, around the industry mean (2.914). P/E Ratio (0.000) is within average values for comparable stocks, (1.904). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (11.052). Dividend Yield (0.000) settles around the average of (0.009) among similar stocks. P/S Ratio (0.130) is also within normal values, averaging (40.124).
The Tickeron Price Growth Rating for this company is 95 (best 1 - 100 worst), indicating slightly worse than average price growth. IVF’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 97 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. IVF’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry MedicalNursingServices
Advertisement